This post-doctoral training grant application is a vital component of the Committee on Clinical Pharmacology and Pharmacogenomics, providing a mechanism for the training of young clinical investigators in preparation for an independent research career in Clinical Pharmacology. The Committee on Clinical Pharmacology and Pharmacogenomics is an interdepartmental unit comprised of faculty in the Departments of Anesthesia and Critical Care, Human Genetics, Medicine, Pediatrics, and Psychiatry, who have a shared interest and background in the principles of clinical pharmacology and pharmacogenomics. The training program also includes other faculty within the Biological Sciences Division who are involved in some aspect of clinical pharmacology and pharmacogenomics. The faculty jointly provide a core of knowledge regarding basic principles: pharmacodynamics and pharmacokinetics, drug disposition and metabolism, drug interactions, and various assay methodologies. Mark J. Ratain, M.D., who is Chairman of the Committee, directs the program along with Michael Maitland, M.D., Ph.D. who was appointed as the Associate Director of Fellow Education. An Executive Committee comprised of three other faculty representing the Committee's membership will advise them. Funding is requested to support the full-time research activities of 5 post- doctoral trainees each year. The majority of these trainees will have medical degrees and be board eligible in their area of specialty. A small number of trainees will hold Ph.D and/or Pharm.D. degrees The program will concentrate on research training that will take place under the supervision of the trainee's preceptor. Each trainee will be expected to enhance his/her education with formal coursework and participation in seminars, journal clubs and directed readings. The trainee will participate in activities such as the Clinical Pharmacology Consult Service, the Institutional Review Board, and the Pharmacy and Therapeutics Committee. A maximum of 10% effort (e.g. one-half day per week) will be allowed for clinical responsibilities in the area of the trainee's specialty. Upon completion of this program, the trainee is expected to become accomplished in basic research methodology, experimental design, and data interpretation and presentation, and be prepared for a competitive academic research career, as well as certification in Clinical Pharmacology.

Public Health Relevance

The training program in Clinical Pharmacology and Pharmacogenomics at the University of Chicago provides the intellectual environment, formal instruction, peer interaction and clinical experience necessary for trainees to acquire knowledge, skills, and attitudes essential to the practice of clinical pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
2T32GM007019-34
Application #
7761826
Study Section
Special Emphasis Panel (ZGM1-BRT-5 (PD))
Program Officer
Okita, Richard T
Project Start
1978-07-01
Project End
2015-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
34
Fiscal Year
2010
Total Cost
$252,621
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
House, Larry; Seminerio, Michael J; Mirkov, Snezana et al. (2018) Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica 48:973-983
Sokol, Elizabeth A; Engelmann, Roger; Kang, Wenjun et al. (2018) Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer 65:e27417
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Arndt, David L; de Wit, Harriet (2017) Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults. Cannabis Cannabinoid Res 2:105-113
Applebaum, Mark A; Desai, Ami V; Glade Bender, Julia L et al. (2017) Emerging and investigational therapies for neuroblastoma. Expert Opin Orphan Drugs 5:355-368
Sweis, Randy F; Luke, Jason J (2017) Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res 120:1-9
Sweis, Randy F; Ratain, Mark J (2017) Obviating the Need for Serial Biopsies Through Random Assignment. J Clin Oncol 35:260
Pettit, Kristen; Odenike, Olatoyosi (2017) Novel Therapies for Myelofibrosis. Curr Hematol Malig Rep 12:611-624
Eadon, Michael T; Hause, Ronald J; Stark, Amy L et al. (2017) Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci 18:
Applebaum, Mark A; Vaksman, Zalman; Lee, Sang Mee et al. (2017) Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer 72:177-185

Showing the most recent 10 out of 107 publications